MEANING: These results did not support the interpretation of ERBB2-low as a distinct biologic subtype of breast cancer.IMPORTANCE: It is unclear whether ERBB2-low breast cancer should be considered an individual biologic subtype distinct from ERBB2-0 breast...
MEANING: These findings suggest that the chemotherapy-free anti-ERBB2 strategy is an option as first-line treatment in some patients with ERBB2-positive metastatic breast cancer. IMPORTANCE: In ERBB2 (formerly HER2)-positive metastatic breast cancer (MBC), combining trastuzumab and pertuzumab with t...
MEANING: These findings suggest that the chemotherapy-free anti-ERBB2 strategy is an option as first-line treatment in some patients with ERBB2-positive metastatic breast cancer. IMPORTANCE: In ERBB2 (formerly HER2)-positive metastatic breast cancer (MBC), combining trastuzumab and pertuzumab with t...
MEANING: Findings showed that 100 μg of ERBB2 ICD plasmid DNA was associated with generation of immunity in most patients, which persisted after the end of vaccinations; enduring immunity was adversely associated with DNA retention at the injection site. I...
MEANING: These findings suggest that the chemotherapy-free anti-ERBB2 strategy is an option as first-line treatment in some patients with ERBB2-positive metastatic breast cancer. IMPORTANCE: In ERBB2 (formerly HER2)-positive metastatic breast cancer (MBC), combining trastuzumab and pertuzumab with ...
Rimm begins by clarifying that the IHC test for HER2 is a companion diagnostic rather than a standard diagnostic test, meaning it is specifically used to determine eligibility for certain therapies. In this case, the companion diagnostic is primarily associated wit...
MEANING: Findings showed that 100 μg of ERBB2 ICD plasmid DNA was associated with generation of immunity in most patients, which persisted after the end of vaccinations; enduring immunity was adversely associated with DNA retention at the injection site. ...
1. What is the impact of HER2 levels in HER2-positive metastatic BC patients treated with standard therapy? 2. Is there room for targeting HER2-negative tumors with low HER2 expression (meaning cases with IHC score 1+ or 2+ not amplified by FISH)? Starting from the first question, the le...
喺2015年12月舉行的乳癌世界大會San Antonio Breast Cancer Symposium之中,發表咗一個重磅研究BCIRG 006嘅10年跟進結果。發現打TTCH同ACTH嘅治療效果一樣,不過TTCH嘅心臟副作用就少好多。可以預期從此以後,TTCH將會一統江湖成為首選,冇咩人會再打ACTH/ACPH。
The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target was a major breakthrough for the treatment of highly aggressive HER2-positive breast cancer, leading to approval of the first HER2-targeted drug — the monoclonal